Gamma Interferon Induced Organ Regeneration

Competing Interests

The author declares that he has no competing interests.


This paper is dedicated to the memory of Dr. Dan E. Pratt, a brilliant scientist and teacher.


[1] Muneoka K, Han M, Gardiner DM. Regrowing human limbs. Sci Am. 2008 Apr;298(4):56-63. 

[2] Gardiner DM. Ontogenetic decline of regenerative ability and the stimulation of human regeneration. Rejuvenation Res. 2005 Fall;8(3):141-53.

[3] Han M, Yang X, Taylor G, Burdsal CA, Anderson RA, Muneoka K.  Limb regeneration in higher vertebrates: developing a roadmap. Anat Rec B New Anat. 2005 Nov;287(1):14-24.

[4] Brockes JP, Kumar A.  Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science. 2005 Dec 23;310(5756):1919-23.

[5] Sharpe RJ.  Endogenous gamma interferon production may protect against hepatic cirrhosis and  administration of exogenous gamma interferon may protect individuals prone to cirrhosis. Med Hypotheses. 1987 Apr;22(4):415-9.

[6] Kalra S, Utz JP, Ryu JH; Mayo Clinic Interstitial Lung Diseases Group.  Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc. 2003 Sep;78(9):1082-7.

[7] American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64.

[8] Cooper JA Jr, White DA, Matthay RA.  Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986 Feb;133(2):321-40.

[9] Araki T, Katsura H, Sawabe M, Kida K.  A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients. Intern Med. 2003 Jun;42(6):483-9.

[10] Edwards SW, Say JE, Hughes V.  Gamma interferon enhances the killing of Staphylococcus aureus by human neutrophils. J Gen Microbiol. 1988 Jan;134(1):37-42.

[11] Chacon RA, Corris PA, Dark JH, Gibson GJ.  Comparison of the functional results of single lung transplantation for pulmonary fibrosis and chronic airway obstruction. Thorax. 1998 Jan;53(1):43-9.

[12] Sharpe RJ, Margolis RJ, Askari M, Amento EP, Granstein RD.  Induction of dermal and subcutaneous inflammation by recombinant cachectin/tumor  necrosis factor (TNF alpha) in the mouse. J Invest Dermatol. 1988 Oct;91(4):353-7.

[13] Farrell MM.  The challenge of adult respiratory distress syndrome during interleukin-2 immunotherapy. Oncol Nurs Forum. 1992 Apr;19(3):475-80.

[14] Hack CE, Aarden LA, Thijs LG.  Role of cytokines in sepsis. Adv Immunol. 1997;66:101-95.

[15] Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008 Apr 18;320(5874):373-6.

[16] Jolles S.  A review of high-dose intravenous immunoglobulin (HDIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol. 2001 Mar;26(2):127-31.

[17] Hanson D, Winterbauer RH, Kirtland SH, Wu R.  Changes in pulmonary function test results after 1 year of therapy as predictors  of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995 Aug;108(2):305-10.